AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, Thermo Fisher Scientific, Veeva Systems, and Alnylam Pharmaceuticals are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of publicly traded companies that focus on using living organisms and biological processes to develop products such as therapeutics, vaccines, diagnostics, and agricultural solutions. These companies often carry high research-and-development costs and face significant scientific and regulatory risks tied to clinical trials and approvals. Investors in biotech stocks look for breakthroughs in areas like genomics, cell therapy, and bioengineering, balancing the sector’s growth potential against its inherent volatility and long commercialization timelines. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
NYSE:ABBV traded down $0.09 during trading hours on Friday, hitting $185.53. The company's stock had a trading volume of 11,606,785 shares, compared to its average volume of 6,243,426. The stock has a fifty day moving average of $185.97 and a 200-day moving average of $186.37. The stock has a market capitalization of $327.72 billion, a P/E ratio of 77.30, a price-to-earnings-growth ratio of 1.62 and a beta of 0.56. AbbVie has a 52-week low of $158.83 and a 52-week high of $218.66. The company has a current ratio of 0.66, a quick ratio of 0.55 and a debt-to-equity ratio of 17.94.
Read Our Latest Research Report on ABBV
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Shares of DHR stock traded down $0.93 during mid-day trading on Friday, hitting $189.54. 6,514,078 shares of the stock were exchanged, compared to its average volume of 3,479,894. The stock's fifty day simple moving average is $192.72 and its two-hundred day simple moving average is $213.59. The stock has a market capitalization of $135.65 billion, a price-to-earnings ratio of 35.90, a P/E/G ratio of 2.66 and a beta of 0.80. Danaher has a 12-month low of $171.00 and a 12-month high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.
Read Our Latest Research Report on DHR
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
Shares of VRTX stock traded down $4.08 during midday trading on Friday, reaching $443.01. 2,581,676 shares of the company traded hands, compared to its average volume of 1,420,737. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm's 50 day simple moving average is $469.67 and its two-hundred day simple moving average is $460.91. The firm has a market cap of $113.76 billion, a PE ratio of -201.37, a price-to-earnings-growth ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals has a 1-year low of $377.85 and a 1-year high of $519.88.
Read Our Latest Research Report on VRTX
Cencora (COR)
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
COR stock traded up $0.80 during midday trading on Friday, hitting $291.49. The stock had a trading volume of 3,890,003 shares, compared to its average volume of 1,537,835. The firm has a market cap of $56.50 billion, a PE ratio of 41.46, a price-to-earnings-growth ratio of 1.31 and a beta of 0.60. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54. Cencora has a 12-month low of $218.65 and a 12-month high of $309.35. The company's 50-day moving average price is $284.83 and its 200 day moving average price is $258.61.
Read Our Latest Research Report on COR
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of NYSE:TMO traded down $1.34 during midday trading on Friday, hitting $402.41. 2,521,302 shares of the company's stock traded hands, compared to its average volume of 1,878,887. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The company has a market cap of $151.91 billion, a PE ratio of 24.34, a P/E/G ratio of 2.99 and a beta of 0.82. The firm's fifty day moving average price is $430.85 and its two-hundred day moving average price is $499.77. Thermo Fisher Scientific has a twelve month low of $390.50 and a twelve month high of $627.88.
Read Our Latest Research Report on TMO
Veeva Systems (VEEV)
Veeva Systems Inc. provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States.
VEEV stock traded up $0.99 during trading on Friday, reaching $280.03. The stock had a trading volume of 3,578,987 shares, compared to its average volume of 1,132,660. Veeva Systems has a 1-year low of $171.10 and a 1-year high of $285.70. The company has a market capitalization of $45.56 billion, a P/E ratio of 69.14, a PEG ratio of 1.89 and a beta of 0.96. The firm has a fifty day moving average price of $230.48 and a 200 day moving average price of $227.83.
Read Our Latest Research Report on VEEV
Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.
ALNY stock traded up $11.69 during trading on Friday, reaching $304.59. The stock had a trading volume of 3,116,157 shares, compared to its average volume of 928,432. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 1-year low of $147.25 and a 1-year high of $306.00. The firm has a fifty day moving average price of $260.38 and a 200 day moving average price of $255.01. The company has a market capitalization of $39.71 billion, a P/E ratio of -140.36 and a beta of 0.17.
Read Our Latest Research Report on ALNY
Further Reading
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
